Of the 60 institutional investors that sold NGM Biopharmaceuticals stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Point72 Asset Management L.P. ($3.20M), Redmile Group LLC ($1.92M), Vanguard Group Inc. ($0.85M), Euclidean Capital LLC ($0.59M), BlackRock Inc. ($0.47M), Woodline Partners LP ($0.34M), and SG Americas Securities LLC ($0 . Cowen cut their price objective on NGM Biopharmaceuticals from $32.00 to $9.00 and set an "outperform" rating on the stock in a . NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.28% and 12.66%, respectively, for the quarter ended September 2022. The Investor Relations website contains information about NGM Biopharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. We are explorers 200+ strong. The stock's 50-day simple moving average is $11.66 and its 200 day simple moving average is $13.36. Get details for NGM Biopharmaceuticals's 2 employees, email format for ngmbio.com and phone numbers. (Address of principal executive offices and zip code) Registrant's telephone number, including area code: (650) 243-5555 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class of Securities Registered In the last 12-months NGM Biopharmaceuticals Inc's revenue was $0.069 billion with a gross profit of $-0.084 billion and an EBITDA of $-0.130 billion. ngm biopharmaceuticals inc false 0001426332 0001426332 2022-10-17 2022-10-17 united states securities and exchange commission washington, d.c. 20549 form 8. Poster presentation to showcase initial data from the Phase 1a monotherapy dose escalation arm of the ongoing Phase 1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in patients with advanced solid tumorsILT2 and ILT4, both upregulated in certain tumor types, are believed to serve as myeloid checkpoints, helping tumors evade immune detection. We are advancing our broad and diverse pipeline of biologic drug candidates, all discovered in-house, with the goal of addressing large unmet medical needs in cancer and other diseases that impact the lives of millions around the world. Data Provided by Refinitiv. 32 Questions at NGM Bio with President, Siobhan Nolan Mangini and CEO, David Woodhouse, NGM Biopharmaceuticals. NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. In the market, a comparison of NGM Biopharmaceuticals Inc. (NGM) and its peers suggest the former has performed considerably weaker. Washington, D.C. 20549. Over the past year the S&P 500 is down -19.74% while NGM is lower by -73.74%. The company's File Number is listed as 001615121. . Learn More. 333 Oyster Point Boulevard, South San Francisco, CA, USA, 94080 . Our expertise in drug discovery and translational development, coupled with the significant resources from our partnership with Merck, is . NGM Biopharmaceuticals Inc ( NGM) is lower by Tuesday morning, with the stock falling -3.52% in pre-market trading to 3.29. NGM Biopharmaceuticals Inc (NGM) stock is up 5.83% while the S&P 500 has gained 0.98% as of 3:32 PM on Friday, Nov 4. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need. The contacts are Carol Ho from South San Francisco CA, David Goeddel . We are focused on harnessing powerful, untapped biology underlying . The Company is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of . Do the numbers hold clues to what lies ahead for the stock? The company's principal address is 333 Oyster Point Blvd, South, San Francisco, CA 94080. Find the latest NGM Biopharmaceuticals, Inc. (NGM) stock quote, history, news and other vital information to help you with your stock trading and investing. Shares of NGM opened at $5.31 on Wednesday. The company can be reached via phone at (650) 243-5555 or via email at ir@ngmbio.com . Date of Report (Date of earliest event reported): October 17, 2022. The company's product pipeline consists of NGM282 . Address. The data displayed is available through open government websites and public online directory. After the activity, the stock price went down -0.81% to $3.69. NGM Biopharmaceuticals is a private biopharmaceutical company using a biology-centric approach to create novel biologics for the treatment of a broad spectrum of life-threatening diseases. The company has 10 contacts on record. NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM ), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced topline efficacy and . Goldman Sachs 43rd Annual Global Healthcare Conference. We work collaboratively and fluidly with open doors and without egos. We are advancing our broad and diverse pipeline of biologic drug candidates, all discovered in-house, with the goal of addressing large unmet medical needs in cancer and other diseases that impact the lives of millions around the world. NGM Biopharmaceuticals | 7,669 followers on LinkedIn. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP. NGM Biopharmaceuticals is Drug Discovery business from United States that founded in 2008 (14 years old in 2022), NGM Biopharmaceuticals business is focusing on NGM Biopharmaceuticals Inc. NGM Biopharmaceuticals headquarter office and corporate office address is located in 333 Oyster Point Boulevard NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. At NGM, innovation is perpetual. Data shows NGM's intraday price has changed -0.37% in last session and -23.53% over the past year. In that particular session, Stock kicked-off at the price of $5.04 while reaching the peak value of $5.67 and lowest value recorded on the day was $4.81. We are advancing a broad and diverse pipeline of innovative biologic therapeutic candidates all generated by our in-house discovery engine based on our scientific understanding of key biological pathways underlying cancer, retinal diseases and liver and metabolic diseases. At NGM, innovation is perpetual. At the end of the latest market close, NGM Biopharmaceuticals Inc. (NGM) was valued at $4.78. NGM282 has Results of Operations and Financial Condition. Disclaimer: This website is not affiliated with NGM Biopharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The stock was acquired at an average price of $4.86 per share, for a total transaction of $373,622.22. Up to 5 NGM Biopharmaceuticals. We are advancing a broad and diverse pipeline of innovative biologic therapeutic candidates all generated by our in-house discovery engine based on our scientific understanding of key biological pathways underlying cancer, retinal diseases and liver and metabolic diseases. The official website for the company is www.ngmbio.com . NGM Biopharmaceuticals Inc. (NGM) is priced at $4.49 after the most recent trading session. Sign up for a free account. The stock current value is $5.61.Recently in News on October 17, 2022, NGM Bio . Do the numbers hold clues to what lies ahead for the stock? We freely share ideas and continually challenge one another to . In 2022, NGM Biopharmaceuticals is currently focus on NGM Biopharmaceuticals Inc sector. engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases . NGM Biopharmaceuticals Inc. NGM Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Phone Number 6505831646. FORM 4. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. South San Francisco, CA 94080 . NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. NGM Biopharmaceuticals Inc's Key Ratios. In the Biotechnology industry, which ranks 106 out of 146 industries, NGM . We are focused on discovering and developing transformative therapeutics for patients across multiple therapeutic areas. Get prepared with the key expectations. NGM Biopharmaceuticals is Drug Discovery in United States that focus on NGM Biopharmaceuticals Inc business. 2022 NGM Biopharmaceuticals. We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. This compares to loss of $0.37 per share a year ago. Type: Company - Public (NGM) Industry: Biotech & Pharmaceuticals. . All Rights Reserved. NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or . United States. | We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. What's Happening with NGM Stock Today. Ngm Biopharmaceuticals, Inc. is a Massachusetts Foreign Corporation filed On October 27, 2022. NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic Cancer. At the very opening of the session, the stock price was $3.90 and reached a high price of $4.845, prior to closing the session it reached the value of $3.69. Explorer Series 1: NGM Bios Discovery Engine, Explorer Series 2: Myeloid Reprogramming and Stromal Checkpoint Programs, Explorer Series 3: NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, NGM Bio Corporate Presentation November 2022. Comparatively, Merck & Co. Inc. (MRK) has moved -0.09% on the day and only 18.31% in the past 12 months. No credit card required. NGM's lead compound, NGM282, is in a Phase 2b study for the treatment of PBC. We are focused on harnessing . South San Francisco, CA. Founded: 2008. NGM BIOPHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 26-1679911 . About NGM Biopharmaceuticals. Company profile for NGM Biopharmaceuticals Inc. including key executives, insider trading, ownership, revenue and average growth rates. Item 2.02. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patients. NGM Biopharmaceuticals last posted its quarterly earnings results on August 4th, 2022. NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. South San Francisco, CA 94080 333 Oyster Point Blvd. Lorem ipsum dolor sit, amet consectetur adipisicing elit. NGM Biopharmaceuticals (NGM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.